Skip to content
OpenCapital
Get started

Oruka Therapeutics, Inc. ORKA Long- term Investments

Long- term Investments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
——

Other financials

Income statement

See full
Revenue-—
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0×0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesNoncurrent.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s long- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s long- term investments?
Oruka Therapeutics, Inc. (ORKA) reported long- term investments of $107.12M in Q1 2026.
How has Oruka Therapeutics, Inc.'s long- term investments changed year-over-year?
Oruka Therapeutics, Inc.'s long- term investments increased by 347.2% year-over-year, from $23.95M to $107.12M.